Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AstraZeneca’s Iressa, Now Resurrected, Faces Daunting U.S. EGFR Market

Executive Summary

AstraZeneca sees an edge on safety for Iressa, which was traditionally perceived as having attractive tolerability relative to other EGFR inhibitors, but firm still has a tough road competing against the omnipresent Tarceva.


Related Content

How To Save A Drug: Iressa’s Return Relied On Consistency Across Totality Of Evidence
Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base
Product Withdrawal Can Be As Hard As Approval: Luveris' 4-Year Journey Ends
AstraZeneca's Hudson Optimistic On Return To Growth In 2017
AstraZeneca Scores Lung Cancer Touchdown, While Clovis Fumbles
How Clovis’ Rociletinib And AstraZeneca’s AZD9291 Development Programs Stack Up
Boehringer Joins Next Generation Via Hanmi EGFR Inhibitor Deal
Boehringer Launches Gilotrif At $5,500/Month, Just Under Entrenched Tarceva
DxS Hopes AstraZeneca's Iressa EU Launch Will Help Build Companion Test Business
AstraZeneca's Iressa Use Narrowed: No New Commercial Patients


Related Companies